Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

541. Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation: a decision analysis

Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation: a decision analysis Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation: a decision analysis Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation: a decision analysis Middlekauff H R, Stevenson W G, Gornbein J A Authors (...) , non-randomised trials were included, since no randomised placebo-controlled trials were found. Specific interventions included in the review Sinus rhythm maintenance with quinidine or amiodarone after cardioversion, or long-term anticoagulation with warfarin. Participants included in the review Patients with chronic or paroxysmal atrial fibrillation in a non-post-operative setting were included. Outcomes assessed in the review The outcomes assessed were successful restoration of sinus rhythm

1995 DARE.

542. Costs and effects of long-term oral anticoagulant treatment after myocardial infarction

Costs and effects of long-term oral anticoagulant treatment after myocardial infarction Costs and effects of long-term oral anticoagulant treatment after myocardial infarction Costs and effects of long-term oral anticoagulant treatment after myocardial infarction van Bergen P F, Jonker J J, van Hot B A, van Domburg R T, Deckers J W, Azar A J, Hofman A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Oral anticoagulant drug treatment programme, including monitoring as well as drugs administered. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population Survivors of myocardial infarction, average age 61, 80% male. Setting Outpatient clinics. The economic study was carried

1995 NHS Economic Evaluation Database.

543. Management of heart failure. IV. Anticoagulation for patients with heart failure due to left ventricular systolic dysfunction. (Abstract)

Management of heart failure. IV. Anticoagulation for patients with heart failure due to left ventricular systolic dysfunction. This article reviews the incidence of arterial thromboembolism in patients with heart failure who are not receiving anticoagulants. We also examine whether more severe ventricular dysfunction increases this incidence and the efficacy and risks of anticoagulation for patients in sinus rhythm.English-language studies referenced in MEDLINE or EMBASE (January 1966 (...) to September 1993) were reviewed. We used the search terms heart failure, congestive; congestive heart failure; heart failure; cardiac failure; and dilated cardiomyopathy in conjunction with the terms anticoagulation, cerebrovascular disorders, stroke, and thromboembolism.All studies with separate data for patients with chronic heart failure not receiving anticoagulants were included. Articles addressing valvular heart disease or heart failure secondary to acute myocardial infarction or Chagas' disease

1994 JAMA

544. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. (Abstract)

Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. The use of long-term oral anticoagulant treatment after myocardial infarction remains controversial because of conflicting findings on mortality in previous trials and the increased risk of bleeding associated with anticoagulants. We have carried out a randomised, placebo (...) -controlled, double-blind, multicentre trial in 3404 hospital survivors of myocardial infarction. Eligible patients were randomly assigned to anticoagulant (nicoumalone or phenprocoumon) or placebo treatment within 6 weeks of discharge. The target prothrombin time was 2.8-4.8 international normalised ratio. During mean follow-up of 37 (range 6-76) months there were 170 deaths among 1700 anticoagulant-treated patients and 189 in 1704 placebo-treated patients (hazard ratio 0.90 [95% CI 0.73-1.11

1994 Lancet Controlled trial quality: predicted high

545. Anticoagulant therapy in the Nordic Countries

Anticoagulant therapy in the Nordic Countries Anticoagulant therapy in the Nordic Countries Anticoagulant therapy in the Nordic Countries Joergensen T, Jespersen J (eds) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Joergensen T, Jespersen J (eds). Anticoagulant therapy in the Nordic Countries. Danish Institute for Health Services (...) Research (DSI). 1994 Authors' objectives Describe state-of-the-art in the Nordic Countries of the use of vitamin-K antagonists in anticoagulant therapy (ACT). Authors' conclusions Quality assurance programmes for ACT should be developed and implemented in clinical departments as well as in primary care. ACT should be concentrated on fewer hands in the clinical unit. Cooperation and communication between clinical departments, the primary health sector and laboratories should be improved. More patients

1994 Health Technology Assessment (HTA) Database.

546. Management of heart failure - IV: anticoagulation for patients with heart failure due to left ventricular systolic dysfunction

Management of heart failure - IV: anticoagulation for patients with heart failure due to left ventricular systolic dysfunction Management of heart failure - IV: anticoagulation for patients with heart failure due to left ventricular systolic dysfunction Management of heart failure - IV: anticoagulation for patients with heart failure due to left ventricular systolic dysfunction Baker D W, Wright R F Authors' objectives To review the effectiveness and associated risks of anticoagulation (...) in patients with heart failure. Searching MEDLINE and EMBASE were searched from 1966 to September 1993 using the search terms given. References from identified articles, textbooks and review articles were also examined. Study selection Study designs of evaluations included in the review Observational studies comparing treated and non-treated patients. Specific interventions included in the review Anticoagulation mainly involving the use of coumarin-based drugs. Participants included in the review Patients

1994 DARE.

547. Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. The CABADAS Research Group of the Interuniversity Cardiology Institute of The Ne (Abstract)

Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. The CABADAS Research Group of the Interuniversity Cardiology Institute of The Ne Aspirin, alone or in combination with dipyridamole, is known to prevent occlusion of aortocoronary vein grafts. The benefit of dipyridamole in addition to aspirin remains controversial, and the efficacy and safety of oral anticoagulants (...) for prevention of vein-graft occlusion have not been established. We assessed one-year angiographic vein-graft patency after aortocoronary-bypass surgery in 948 patients assigned to receive aspirin, aspirin plus dipyridamole, or oral anticoagulants in a prospective, randomised trial. The design was double-blind and placebo-controlled for the aspirin groups, but open for oral anticoagulant treatment. Dipyridamole (5 mg/kg per 24 h intravenously for 28 h, followed by 200 mg twice daily) and oral anticoagulants

1993 Lancet Controlled trial quality: predicted high

548. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. (Abstract)

Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. The optimum duration of anticoagulation therapy for deep-vein thrombosis (DVT) and pulmonary embolism (PE) is not clear. We have carried out a multicentre comparison of 4 weeks' and 3 months' anticoagulation in patients admitted to hospital with acute DVT, PE, or both. Of 712 patients enrolled, 358 were assigned 4 weeks' treatment and 354 3 months'. Objective (...) the rate of treatment failure and recurrence was low (2.6%) and there was little difference between the treatment groups. By contrast, among medical patients the rate was 12.8%, with a clear difference in favour of 3 months' treatment. If venous thromboembolism arises after surgery, 4 weeks of anticoagulation should be adequate. In other settings, patients with new DVT, PE, or both, who do not have a persisting underlying cause or risk factor should receive anticoagulants for 3 months.

1992 Lancet Controlled trial quality: uncertain

549. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. (Abstract)

Trial of different intensities of anticoagulation in patients with prosthetic heart valves. We compared the efficacy and complications of anticoagulation with warfarin in 258 patients with prosthetic heart valves treated with regimens of "moderate intensity" (prothrombin-time ratio, 1.5; international normalized ratio, 2.65) or "high intensity" (prothrombin-time ratio, 2.5; international normalized ratio, 9) in a prospective, randomized study. The two patient groups were followed up for 421 (...) , as compared with 10.1 episodes in the high-intensity group (P less than 0.01). Major bleeding was also more common in the high-intensity group (2.1 episodes per 100 patient-years--including the only two fatal hemorrhages--as compared with 0.95 episode in the moderate-intensity group), but the difference was not statistically significant. We conclude that a moderate anticoagulant effect (prothrombin-time ratio, about 1.5) in patients with a mechanical prosthetic heart valve offers protection equivalent

1990 NEJM Controlled trial quality: uncertain

550. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. (Abstract)

The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. Nonrheumatic atrial fibrillation increases the risk of stroke, presumably from atrial thromboemboli. There is uncertainty about the efficacy and risks of long-term warfarin therapy to prevent stroke.We conducted an unblinded, randomized, controlled trial of long-term, low-dose warfarin therapy (target prothrombin

1990 NEJM Controlled trial quality: predicted high

551. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. (Abstract)

Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. We carried out a placebo-controlled, double-blind, randomized study of the hemostatic effect of tranexamic acid mouthwash after oral surgery in 39 patients receiving anticoagulant agents because of the presence of cardiac valvular stenosis, a prosthetic cardiac valve, or a vascular prosthesis. Surgery was performed with no change in the level of anticoagulant therapy, and treatment (...) with the anticoagulant agent was continued after surgery. Before it was sutured, the operative field was irrigated in 19 patients with 10 ml of a 4.8 percent aqueous solution of tranexamic acid (an inhibitor of fibrinolysis) and in 20 patients with a placebo solution. For seven days thereafter, patients were instructed to rinse their mouths with 10 ml of the assigned solution for two minutes four times a day. There were no significant differences between the two treatment groups in base-line variables, including

1989 NEJM Controlled trial quality: uncertain

552. Trial of low-dose aspirin plus dipyridamole versus anticoagulants for prevention of aortocoronary vein graft occlusion. (Abstract)

Trial of low-dose aspirin plus dipyridamole versus anticoagulants for prevention of aortocoronary vein graft occlusion. In a prospective randomised trial, 249 patients who had aortocoronary vein bypass surgery were assigned either to a platelet inhibitory drug regimen or to standard anticoagulant therapy. Treatment was replaced by placebo in half of the patients in each group after 3 months. The platelet inhibitory drug regimen--very low-dose aspirin combined with dipyridamole--was as effective (...) as standard anticoagulant therapy to prevent early and late graft occlusion. Death, myocardial infarction, and severe bleeding occurred significantly more often in patients receiving anticoagulants, whereas mild drug-related gastrointestinal and cerebral side-effects were more common in patients taking platelet inhibitory drugs. Antithrombotic treatment should be continued for at least 1 year after coronary artery bypass graft surgery.

1989 Lancet Controlled trial quality: uncertain

553. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. (Abstract)

Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. After tissue heart valve replacement 108 patients were randomised to standard anticoagulant control with rabbit brain thromboplastin (Dade C reagent, therapeutic range 18-24 s; international normalised ratio 2.5-40) and 102 to a less intensive regimen controlled with human brain thromboplastin (Manchester Comparative Reagent, therapeutic range 26-30 s; INR 2.0-2.25). Treatment (...) complications, all were in the standard treatment group, again a significant difference. The less intensive regimen is thus no less effective and safer than standard anticoagulant therapy in patients with tissue heart valve replacement.

1988 Lancet Controlled trial quality: uncertain

554. Influence of postoperative anticoagulant treatment on patient survival after femoropopliteal vein bypass surgery. (Abstract)

Influence of postoperative anticoagulant treatment on patient survival after femoropopliteal vein bypass surgery. To examine whether anticoagulants given after autologous saphenous bypass surgery influenced patient survival 119 patients who received such a graft for obliterative arterial disease were recruited for a controlled clinical trial. Patients were randomly assigned to start, in the second postoperative week, phenprocoumon (60 patients) or no treatment (59 patients). The median duration

1988 Lancet Controlled trial quality: uncertain

555. Is a controlled trial of long-term oral anticoagulants in patients with stroke and non-rheumatic atrial fibrillation worthwhile? (Abstract)

Is a controlled trial of long-term oral anticoagulants in patients with stroke and non-rheumatic atrial fibrillation worthwhile? A controlled randomised trial large enough to assess the value of anticoagulating stroke patients in atrial fibrillation would be difficult to conduct in the UK and the results would be applicable to only a small proportion of stroke patients. It would be more worthwhile to organise a trial that also assessed the value of other treatments that are simpler (...) and applicable to all stroke patients. A trial that assessed the value of aspirin and beta-blockers against control in all stroke patients would not cost much more than one restricted to comparing anticoagulants against control in patients with stroke and atrial fibrillation but would provide information of more relevance to the management of patients with stroke in the UK.

1986 Lancet

556. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. (Abstract)

Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. The need for oral anticoagulation in patients with calf-vein thrombosis was examined in a randomised study of 51 patients, of whom 23 received warfarin for 3 months and 28 did not. Both groups received an initial course of heparin and all wore compression stockings. Progress was monitored by the use of serial isotope tests and physical examination. Phlebography was repeated if recurrence was suspected. During (...) the first 3 months, 8 patients in the non-warfarin group (29%) had recurrences compared with none in the warfarin group (p less than 0.01). 5 patients had recurrence with proximal extension and 1 patient had a pulmonary embolus. After 1 year, 22 out of 23 patients in the warfarin group had not had a recurrence, compared with 19 out of 28 (p less than 0.02). The findings indicate that oral anticoagulants should be given to all patients with thrombi that produce symptoms. Treatment for 3 months seems

1985 Lancet Controlled trial quality: uncertain

557. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. (Abstract)

A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. Although neither aspirin nor oral anticoagulants have been conclusively shown to reduce mortality in patients surviving myocardial infarction, both have been widely used for that purpose. In the present clinical trial we compared the effects of aspirin (0.5 g given three times a day) and oral-anticoagulant therapy. Of 6908 patients considered for entry, 1303 were randomized (...) to anticoagulant (652) or aspirin (651) an average of 11.4 days after the onset of myocardial infarction and were followed for 6 to 59 months (mean, 29 months). There were 65 deaths in the anticoagulant group and 72 in the aspirin group. The number of patients with reinfarctions was higher in the aspirin group (33 vs. 20). None of these differences were statistically significant. Almost twice as many patients were withdrawn from therapy in the aspirin group. There were 54 per cent more patients

1982 NEJM Controlled trial quality: uncertain

558. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. (Abstract)

Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. We have previously reported that long-term therapy with warfarin is effective for preventing recurrent venous thromboembolism in patients with proximal-vein thrombosis but that there is an appreciable risk of hemorrhage. To determine whether that risk could be reduced without a loss of effectiveness, we randomly allocated 96 patients with proximal-vein thrombosis to a group receiving less intense (...) anticoagulant therapy, with a mean prothrombin time of 26.9 seconds using the Manchester comparative reagent (corresponding Simplastin time, 15 seconds), or a group given more intense therapy, with a mean Simplastin time of 19.4 seconds (corresponding prothrombin time 41 seconds with the Manchester comparative reagent) (P less than 0.001). Two of 47 patients (4 per cent) in the less intensely treated group had hemorrhagic complications, as compared with 11 of 49 patients (22 per cent) in the more intensely

1982 NEJM Controlled trial quality: uncertain

559. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group. (Abstract)

A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group. In a randomised double-blind multicentre clinical trial the effect of continued oral anticoagulant therapy after a myocardial infarction was assessed in a group of patients over 60 years of age. Half of the 878 patients who had been on anticoagulants ever since their primary myocardial infarction received placebos (...) instead of the anticoagulant; the others continued anticoagulant therapy. All were followed for 2 years. The levels of hypocoagulability reached in the group on anticoagulants were such that, of the registered prothrombin times ('Thrombotest'), 72% were between 107 and 180 s. 2-year total mortality was 13.4% in the placebo group and 7.6% in the group treated with anticoagulants (p = 0.017. 2-year incidence of recurrent myocardial infarction was 15.9% in the placebo group and 5.7% in the anticoagulant

1980 Lancet Controlled trial quality: predicted high

560. Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronary-artery bypass: a controlled, randomized study. (Abstract)

Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronary-artery bypass: a controlled, randomized study. Fifty patients who underwent aortocoronary saphenous-vein bypass-graft surgery were randomly assigned to one of three groups to determine the effects of antiplatelet or anticoagulant therapy on graft patency. Twenty-four patients served as controls; 13 patients received aspirin (325 mg three times a day) and dipyridamole (75 mg three times a day); and 13

1979 NEJM Controlled trial quality: uncertain